Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week double-blind monotherapy study of roluperidone for negative symptoms in schizophrenia with 40-week relapse-prevention phase
2026-525925-19-00Phase 3Authorised
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of roluperidone in schizophrenia (4 arms), sponsored by Minerva Neurosciences, Inc. Primary endpoint: Change from Baseline in NSFS. Planned start Sep 2026; status: authorised.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2026-525925-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525925-19-00.